FRI0137 medication interval of adalimumab for rheumatoid arthritis patients might be extended after the achievement of low disease activity-kabuki study

Authors
Category Primary study
Year 2015
This article has no abstract
Epistemonikos ID: c5dfb1e837fdbfae50be2ef8f6ff9e6744a2eab7
First added on: Dec 18, 2021